Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth
Tata Asset Management Limited · Direct Plan · Growth
Fund overview
0.25% on or before 15D, Nil after 15D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,758 | +758 |
| 3 Years | ₹5,000 | ₹7,636 | +2,636 |
| 5 Years | ₹5,000 | ₹10,127 | +5,127 |
Calculated using the fund's annualised return since inception (15.2% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
30 securitiesTop 10 holdings make up 55.3% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 11.84% |
| Lupin Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 7.57% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 7.09% |
| Fortis Healthcare Ltd | Healthcare Services | Mid Cap | 6.16% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.40% |
| Alkem Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.78% |
| Mankind Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.36% |
| Ipca Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.11% |
| Biocon Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.96% |
| Gland Pharma Ltd | Pharmaceuticals & Biotechnology | Small Cap | 3.55% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹221 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹221 Cr
Exit load, stamp duty & tax
26-Apr-24
0.25% on or before 15D, Nil after 15D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | -- |
| Beta | -- |
| Sharpe Ratio | -- |
| Sortino Ratio | -- |
| Treynor Ratio | -- |
| Jensen's Alpha | -- |
| Information Ratio | -- |
| R-Squared | -- |
| Max Drawdown | -- |
| Upside Capture | -- |
| Downside Capture | -- |
Fund management
Scheme Details
Investment objective
The Investment Objective Of The Scheme Is To Provide Returns, Before Expenses, That Are In Line With The Performance Of Nifty Midsmall Healthcare Index (Tri), Subject To Tracking Error.
Fund house
Tata Asset Management Limited
Frequently asked questions
What is the NAV of Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth?
The NAV of Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth is ₹14.21 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth?
The expense ratio charged by Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth is 0.56%.
What is the Min. SIP of Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth?
The minimum SIP investment in Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth is ₹100 per month.
What is the Min. Lumpsum of Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth?
The minimum lumpsum investment in Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth is ₹5,000.
What is the Exit Load of Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth?
The exit load for Tata NIFTY MidSmall Healthcare Index Fund - Direct Plan - Growth is: 0.25% on or before 15D, Nil after 15D
.svg){kind=small}